Search research articles
Contact Us
Filters
Showing results (21-30 of 42) with videos related to
Page
of 5
Sort By:
The American Journal of Cardiology
|
December 26, 2024
Comparison of Alcohol Septal Ablation With Mavacamten in Obstructive Hypertrophic Cardiomyopathy
Ashraf Samhan, Danish Saleh, Ellis Y Kim, et al.
Journal of Cardiovascular Development and Disease
|
January 27, 2026
Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy
Danish Saleh, Ellis Y Kim, Kifah Hussain, et al.
JACC. Heart Failure
|
January 4, 2024
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort
Florian Rader, Artur Oręziak, Lubna Choudhury, et al.
Journal of the American College of Cardiology
|
December 17, 2021
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
Sheila M Hegde, Steven J Lester, Scott D Solomon, et al.
Journal of the American Heart Association
|
May 18, 2024
Reduction of Filamin C Results in Altered Proteostasis, Cardiomyopathy, and Arrhythmias
Joyce C Ohiri, Lisa Dellefave-Castillo, Garima Tomar, et al.
European Heart Journal
|
September 1, 2024
Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy
Pablo Garcia-Pavia, Artur Oręziak, Ahmad Masri, et al.
European Heart Journal
|
March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study
Albree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
Journal of the American College of Cardiology
|
April 10, 2024
Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy
Martin S Maron, Masliza Mahmod, Azlan Helmy Abd Samat, et al.
Journal of the American College of Cardiology
|
May 30, 2020
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy
Carolyn Y Ho, Matthew E Mealiffe, Richard G Bach, et al.
Journal of the American College of Cardiology
|
October 30, 2024
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM
Ahmad Masri, Lubna Choudhury, Roberto Barriales-Villa, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 42) with videos related to
Sort By:
Page
of 5
The American Journal of Cardiology
|
December 26, 2024
Comparison of Alcohol Septal Ablation With Mavacamten in Obstructive Hypertrophic Cardiomyopathy
Ashraf Samhan, Danish Saleh, Ellis Y Kim, et al.
Journal of Cardiovascular Development and Disease
|
January 27, 2026
Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy
Danish Saleh, Ellis Y Kim, Kifah Hussain, et al.
JACC. Heart Failure
|
January 4, 2024
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort
Florian Rader, Artur Oręziak, Lubna Choudhury, et al.
Journal of the American College of Cardiology
|
December 17, 2021
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy
Sheila M Hegde, Steven J Lester, Scott D Solomon, et al.
Journal of the American Heart Association
|
May 18, 2024
Reduction of Filamin C Results in Altered Proteostasis, Cardiomyopathy, and Arrhythmias
Joyce C Ohiri, Lisa Dellefave-Castillo, Garima Tomar, et al.
European Heart Journal
|
September 1, 2024
Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy
Pablo Garcia-Pavia, Artur Oręziak, Ahmad Masri, et al.
European Heart Journal
|
March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study
Albree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
Journal of the American College of Cardiology
|
April 10, 2024
Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy
Martin S Maron, Masliza Mahmod, Azlan Helmy Abd Samat, et al.
Journal of the American College of Cardiology
|
May 30, 2020
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy
Carolyn Y Ho, Matthew E Mealiffe, Richard G Bach, et al.
Journal of the American College of Cardiology
|
October 30, 2024
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM
Ahmad Masri, Lubna Choudhury, Roberto Barriales-Villa, et al.
Page
of 5